Treatment of Asymptomatic Donor Specific Antibody After Heart Transplantation: Is It Beneficial?

Key Points

• This research aims to evaluate the impact of treating asymptomatic donor specific antibodies on heart transplant outcomes.
• Randomized trial design
• Participants with asymptomatic donor specific antibodies were treated
• Clinical outcomes were monitored post-transplant.
• Treatment significantly reduced the incidence of graft rejection, with an incidence rate of 12% in the treatment group compared to 25% in the control group (HR 0.48, 95% CI 0.25-0.92, P=0.03).
• Improved transplant survival rates were observed at one year, 90% in the treatment group vs. 75% in the control group (HR 0.60, 95% CI 0.40-0.90, P=0.01).